Reckitt Benckiser Group PLC

Reckitt Benckiser Group Plc engages in the manufacture and trade of consumer brand products including Air Wick, Calgon, Cillit Bang, Clearasil, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, and Woolite. It operates through the following segments: Hygiene, Health, and Nutrition. The company was founded by Johann A. Benckiser in 1823 and is headquartered in Slough, the United Kingdom.

Apollo Global Management

Private equity groups Advent International and Apollo Global are among firms mulling a potential buyout of British consumer goods company Reckitt's homecare assets, Bloomberg News reported on Wednesday, citing people familiar with the matter.

Advent, Apollo among potential bidders for Reckitt's homecare assets, Bloomberg News reports

Abbott Labs

Shares of Abbott Laboratories (ABT) are rising and those of Reckitt Benckiser are gaining in London trading Friday, a day after a jury cleared the two infant formula makers of liability for a boy's debilitating intestinal disease.

Abbott, Reckitt Stocks Gain as Baby Formula Makers Score Rare Legal Win

Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB)  got the 'best case scenario' result in the Whitfield trial in Missouri, say analysts at Barclays, as all the infant formula NEC liability claims were dismissed. Plaintiffs were seeking $6bn of damages with Barclays saying that investors were building in a substantial damages award against the company and its subsidiary AMV.

Reckitt Benckiser got 'best-case' outcome in latest US infant formula trial, broker suggest

Shares in Reckitt Benckiser topped the Stoxx Europe 600 Index after a U.S. court cleared the company of liability in a case concerning its baby formulas.

Reckitt Shares Surge After Baby Formula Lawsuit Win

A court in St. Louis, Missouri ruled in favor of Abbott Laboratories and Reckitt Benckiser over claims their specialized baby formula caused users to develop a bowel disease called NEC

Abbott Labs and Reckitt Benckiser shares surge on court's baby formula ruling

Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB) shares climbed over 10% on Friday morning after the consumer group was cleared in the latest trial on disease risks related to baby formula. A court in Missouri on Thursday rejected claims that formula made by Reckitts' Mead Johnson division, alongside Abbott, caused inflammation of the bowel, or necrotizing enterocolitis, which can require invasive surgery.

Reckitt Benckiser shares jump after clearance in latest baby formula trial

Shares in British consumer goods company Reckitt Benckiser jumped over 10% on Friday after the company, along with U.S.-based Abbott Labs, was cleared of liability in a preterm formula case.

Reckitt Benckiser up 10% after being cleared of liability in preterm formula case

Abbott and Reckitt unit Mead Johnson are not responsible for a young boy's debilitating intestinal disease, a jury found on Thursday in a lawsuit accusing them of failing to warn of their premature baby formulas' risks, a victory for the two companies following large losses in similar trials.

Abbott, Reckitt cleared of liability in latest preterm formula case

A lawyer for a Missouri mother on Wednesday asked a jury to make Abbott and Reckitt's Mead Johnson pay a total of more than $6 billion in the latest trial over claims that the companies' formulas for premature babies caused a severe intestinal illness.

Jury asked to award more than $6 billion in preterm formula case against Abbott, Reckitt's Mead

Reckitt Benckiser Group plc (OTCPK:RBGPF) Q3 2024 Results Conference Call October 23, 2024 3:30 AM ET Company Participants Nick Ashworth - Head of Investor Relations Kris Licht - Chief Executive Officer Shannon Eisenhardt - CFO & Executive Director Conference Call Participants Rashad Kawan - Morgan Stanley Iain Simpson - Barclays Guillaume Delmas - UBS Jeremy Fialko - HSBC Celine Pannuti - JP Morgan David Hayes - Jefferies Victoria Petrova - Bank of America Jeff Stent - Exane BNP Paribas Tom Sykes - Deutsche Bank Nick Ashworth Good morning, and welcome to Reckitt's Q3 trading update. Our CEO, Kris Licht, and our CFO, Shannon Eisenhardt, will take you through some prepared remarks followed by Q&A.

Reckitt Benckiser Group plc (RBGPF) Q3 2024 Earnings Call Transcript

Clorox

Investors interested in Soap and Cleaning Materials stocks are likely familiar with Reckitt Benckiser Group PLC (RBGLY) and Clorox (CLX). But which of these two stocks offers value investors a better bang for their buck right now?

RBGLY or CLX: Which Is the Better Value Stock Right Now?

Shares in Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB) rose almost 4% to a six-month high after the Cilit Bang, Nurofen and Durex maker reported a smaller fall in sales than investors feared. Third-quarter numbers showed group organic sales down 0.5%, beating the average City analyst forecast for a 1.7% decline.

Reckitt Benckiser results 'good enough' but not out of the woods yet

Lysol maker Reckitt Benckiser's revenue fell by less than expected in the third quarter as declines in sales volumes eased, and confirmed its targets for the full year.

Lysol Maker Reckitt Benckiser Beats Views as Easing Prices Draw Shoppers

Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB) has said sales fell over the third quarter as revenue from its nutrition wing slumped. Like for like revenue declined by 0.5% to £3,46 billion during the quarter, the consumer goods firm said, or by 4.0% on an international reporting standards basis.

Reckitt Benckiser posts drop in revenue as nutrition wing weighs

Reckitt reported a smaller than expected fall in third-quarter underlying sales on Wednesday, helped by its health business, which makes Nurofen painkillers and Strepsils lozenges.

Healthcare helps Reckitt beat quarterly sales estimates

Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB) will offer up third-quarter results next Wednesday, 23 October reflecting what analysts believe will have seen a drop in sales. Barclays analysts forecast organic sales growth to have fallen by 1.2% over the quarter as weaker prices offset volume growth.

Reckitt promotional push threatens sales as earnings loom

Investors looking for stocks in the Soap and Cleaning Materials sector might want to consider either Reckitt Benckiser Group PLC (RBGLY) or Clorox (CLX). But which of these two stocks is more attractive to value investors?

RBGLY vs. CLX: Which Stock Is the Better Value Option?

Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB) could return up to £12.5 billion to shareholders, about 40% of its market value, as part of a major strategic overhaul, according to Barclays. The company plans to shift from a category-first model to a geography-first approach, with asset sales playing a key role.

Reckitt Benckiser could return £12.5bn after overhaul, says leading investment bank

Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB) is facing multiple challenges ahead of its third-quarter results, with Jefferies forecasting a -1% drop in like-for-like sales. Key reasons for the limp forecast include weaker scanner data from the US and the impact of a tornado on the company's nutrition segment, which is expected to be heavily weighted in the third quarter.

Reckitt Benckiser has sales and legal risks aplenty as third-quarter results approach

A Missouri mother and her lawyers this week will aim to convince a jury that Abbott , Reckitt's Mead Johnson and St. Louis Children's Hospital are responsible for a severe intestinal illness that she says her premature son got from the companies' formulas after he was born at the hospital.

Abbott, Reckitt face trial over premature baby formula amid alarm from doctors

Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB) is in talks with interested parties to dispose of its £6 billion homecare portfolio, which includes household brands Air Wick, Mortein, Calgon and Cillit Bang, Bloomberg has reported. The reported discussions align with an announcement from the FTSE 100-listed FMCG giant in July that plans to get rid of certain non-core products from its portfolio.

Reckitt in talks to sell £6bn homecare portfolio, reports Bloomberg

Reckitt Benckiser has initiated early discussions with potential suitors for a sale of its homecare assets, which could be worth over 6 billion pounds ($7.89 billion), Bloomberg News reported on Tuesday.

Reckitt initiates discussions on $7.9 billion homecare assets sale, Bloomberg reports

Adobe

Allianz SE

Bank of Nova Scotia

Cigna

Canadian National Railway Company

Enterprise Products Partners

Siemens AG

UnitedHealth Group

The economy is stable but cooling, with the labor market showing signs of slowing down. GDP growth is likely to keep falling, and individual companies could suffer. Long-term investors should focus on companies with strong risk management and adaptability to changing economic conditions, ensuring consistent returns and dividend growth. These 10 companies average an A-credit rating and S&P risk management in the top 0.4% of global companies.

10 High-Yield A-Rated Blue-Chips For Potentially Scary Times Ahead

Haleon PLC

While the FTSE 100 continues to suffer its worst session in recent times, dropping 2.5%, there are a handful of companies which have been able to buck the bearish trend.  Out of London's blue chips, only Haleon and Reckitt have been able to lift into the green, up by 0.1% and 0.4% respectively.

Haleon, Reckitt, Wizz Air: Stocks lifting despite global sell-off

Shares of Abbott Laboratories and U.K.-listed Reckitt Benckiser both drop after a Missouri jury rules against the American healthcare company.

News for Reckitt Benckiser Group PLC Stock (RBGLY)